Aethlon Medical said it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC as exclusive financial advisor to review potential transactions. The review will consider options such as partnerships, mergers, acquisitions and other alternatives, with no set timeline and no assurance that a transaction will occur. The company also plans to submit safety data from the second cohort of its Australian oncology trial to an independent Data Safety Monitoring Board for review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief on March 12, 2026, and is solely responsible for the information contained therein.